These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

775 related items for PubMed ID: 26878440

  • 1. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A, Quirit JG, Khouri MG, Firestone GL.
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [Abstract] [Full Text] [Related]

  • 2. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.
    Poindexter KM, Matthew S, Aronchik I, Firestone GL.
    Cell Biol Toxicol; 2016 Apr; 32(2):103-19. PubMed ID: 27055402
    [Abstract] [Full Text] [Related]

  • 3. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M.
    Kundu A, Khouri MG, Aryana S, Firestone GL.
    Carcinogenesis; 2017 Dec 07; 38(12):1207-1217. PubMed ID: 29028954
    [Abstract] [Full Text] [Related]

  • 4. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.
    Proc Natl Acad Sci U S A; 2017 Jul 18; 114(29):E5930-E5939. PubMed ID: 28684402
    [Abstract] [Full Text] [Related]

  • 5. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 18; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 6. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376192
    [Abstract] [Full Text] [Related]

  • 7. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H.
    J Invest Dermatol; 2015 Jul 01; 135(7):1863-1872. PubMed ID: 25789707
    [Abstract] [Full Text] [Related]

  • 8. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar 01; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 9. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.
    PLoS One; 2013 Mar 01; 8(8):e72692. PubMed ID: 24023633
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC, Matalka MS.
    Clin Ther; 2012 Jul 01; 34(7):1474-86. PubMed ID: 22742884
    [Abstract] [Full Text] [Related]

  • 13. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.
    Nat Commun; 2014 Dec 15; 5():5712. PubMed ID: 25502142
    [Abstract] [Full Text] [Related]

  • 14. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.
    Arch Dermatol Res; 2014 Dec 15; 306(10):873-84. PubMed ID: 25073704
    [Abstract] [Full Text] [Related]

  • 15. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Aida S, Sonobe Y, Tanimura H, Oikawa N, Yuhki M, Sakamoto H, Mizuno T.
    Cancer Lett; 2017 Nov 28; 409():116-124. PubMed ID: 28923400
    [Abstract] [Full Text] [Related]

  • 16. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.
    Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M.
    Lab Invest; 2017 Feb 28; 97(2):217-227. PubMed ID: 28067893
    [Abstract] [Full Text] [Related]

  • 17. Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Margheri F, Laurenzana A, Fibbi G, Pimpinelli N, Calorini L.
    Cancer Lett; 2017 Nov 01; 408():43-54. PubMed ID: 28826720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
    Feng JH, Nakagawa-Goto K, Lee KH, Shyur LF.
    Mol Cancer Ther; 2016 Jun 01; 15(6):1163-76. PubMed ID: 27048951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.